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Eslicarbazepine acetate is an anticonvulsant drug with a recent U.S. Food and Drug Administration 
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stability study at room temperature or under refrigeration (2°C to 8°C). The stability samples were 
withdrawn at pre-determined time points and analyzed by visual inspection, pH measurement, and a 
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upon shaking. Two suspensions in 50:50 v/v mixtures of Ora-Sweet or Ora-Sweet SF with Ora-Plus were 
selected as the lead formulations for the two-month stability study. At the initiation of the study, all 
samples appeared as white and smooth suspensions with pH ranging from 4.39 to 4.46. The high-
performance liquid chromatographic results confirmed that the initial samples contained 100.4% to 
102.2% of the label claim strength. Over two months of storage at room temperature or refrigeration, 
there were no significant changes in visual appearance, re-suspendability, pH, or potency for any samples. 
No new degradation peaks were observed in any highperformance liquid chromatograms. Based on the 
study results, two eslicarbazepine acetate suspensions are recommended for extemporaneous 
compounding from Aptiom tablets. The formulations consist of 40 mg/mL eslicarbazepine acetate in 
50:50 v/v Ora-Sweet:Ora-Plus or Ora-Sweet SF:Ora-Plus. Once prepared, these suspensions can be stored 
at room temperature or under refrigeration for up to two months. 
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INTRODUCTION
Eslicarbazepine acetate (ESL) is an anti­
convulsant drug indicated for the treatment 
of partial-onset seizures.^ Recently, ESL has 
received U.S. Food and Drug Administration 
(FDA) approval for expanded use in chil­
dren and adolescents 4 to 17 years of age.^
Currently, ESL is only available as 200-mg 
to 800-mg strength tablets in the U.S. under 
the brand name of Aptiom. With the pres­
ence of excipients, the total weight of each 
Aptiom tablet ranges from 235 mg to 933 mg 
(Unofficial laboratory data generated by the 
investigators using one lot of Aptiom tab­
lets for each strength [n=10]). Swallowing 
these large size tablets presents significant 
challenges to many pediatric patients, and 
elderly patients with dysphagia.®'^ An alter­
native solution to overcome this barrier is to 
prepare liquid suspensions from the tablet 
dosage forms. The bioequivalence has been 
established for ESL between the tablet and 
suspension dosage forms at the 800-mg dose 
level in healthy volunteers.® Another recent
Eslicarbazepine acetate is an anticonvulsant drug with a recent U.S. Food and 
Drug Administration approval for expanded use in children and adolescents. 
Currently, eslicarbazepine acetate is only available in the U.S. as 200-mg to 
800-mg strength tablets (Aptiom), which are not easy to administer for 
pediatric patients. This study was initiated to develop an oral suspension 
formulation for extemporaneous compounding by pharmacists and to 
generate stability data for storage recommendations. Nine suspension 
formulations of eslicarbazepine acetate were prepared from Aptiom tablets 
and commercially available liquid vehicles using the standard mortar/pestle 
method. The vehicles varied mainly in their solvents, viscosities, and 
sweeteners. The formulations were evaluated for ease of preparation, physical 
properties, and initial potency. Two lead formulations were selected for a two- 
month stability study at room temperature or under refrigeration (2°C to 8°C). 
The stability samples were withdrawn at pre-determined time points and 
analyzed by visual inspection, pH measurement, and a stability-indicating 
high-performance liquid chromatographic assay. The majority of the 9 
formulations were found to be easy to prepare and administer at a 
concentration of 40-mg/mL eslicarbazepine acetate. Particle settling was 
observed in several formulations over time, but they were re-suspended 
satisfactorily upon shaking. Two suspensions in 50:50 v/v mixtures of Ora- 
Sweet or Ora-Sweet SF with Ora-Plus were selected as the lead formulations 
for the two-month stability study. At the initiation of the study, all samples 
appeared as white and smooth suspensions with pH ranging from 4.39 to 4.46. 
The high-performance liquid chromatographic results confirmed that the 
initial samples contained 100.4% to 102.2% of the label claim strength. Over 
two months of storage at room temperature or refrigeration, there were no 
significant changes in visual appearance, re-suspendability, pH, or potency for 
any samples. No new degradation peaks were observed in any high- 
performance liquid chromatograms. Based on the study results, two 
eslicarbazepine acetate suspensions are recommended for extemporaneous 
compounding from Aptiom tablets. The formulations consist of 40 mg/mL 
eslicarbazepine acetate in 50:50 v/v Ora-Sweet:Ora-Plus or Ora-Sweet 
SF:Ora-Plus. Once prepared, these suspensions can be stored at room 
temperature or under refrigeration for up to two months.
publication also confirmed that the oral 
bioavailability of ESL was similar between 
the crushed tablets (taken with applesauce) 
and intact tablets.®
The authors are affiliated with Wegmans School of Pharmacy, St. John Fisher College, Rochester, 
New York.
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All retail and hospital pharmacists are 
trained in extemporaneous compounding 
and can prepare suspensions from imme­
diate-release tablets, such as Aptiom tab­
lets. A variety of oral suspension vehicles 
are available commercially to facilitate the 
preparation of oral suspensions, and they
include both sugar-based (SB) and sugar- 
free (SF) grades. Due to the relatively high 
dose of ESL, formulation screening should 
be carried out to optimize the palatability 
and physical properties of the suspension 
formulations. The first objective of this 
study was to identify two oral suspension
RECOMMENDED FORMULA AND COMPOUNDING PROCEDURES FOR A 30-ML BATCH OF A 
40-MG/ML ESLICARBAZEPINE ACETATE ORAL SUSPENSION
INGREDIENT
Aptiom Tablet, 600 mg® 
Suspension Vehicle*'
AMOUNT
2 tablets 
qs 30 mL
“Other strengths of Aptiom tablets may be used, and the number of tablets should be re-calculated accordingly 
to provide the same total amount of esiicarbazepine acetate.
‘’The suspension vehicle is a mixture of 50:50 v/v Ora-Sweet:Ora-Plus or Ora-Sweet SF:Ora-Plus (from Perrigo 
Pharmaceuticals). Include at least 20% overage to account for loss during transfer. For example, prepare at least 
36 mL premix for the 30-mL batch of the suspension.
1. Calculate the required quantity of each ingredient for the total amount to be prepared.
2. Prepare the suspension vehicle by mixing 18 mL of Ora-Sweet (or Ora-Sweet SF) and 18 mL of Ora Plus. 
Note: This includes 20% overage to account for loss during transfer.
3. Pre-caiibrate a 2-oz amber plastic prescription bottle with purified water for 30 mL.
4. Place the two Aptiom tablets in a 4-oz glass mortar.
5. Crush the tablets and triturate thoroughly to a fine powder.
6. Add 10 mL of suspension vehicle to the mortar in -2-mL increments and triturate until a smooth suspension 
is obtained.
7. Pour the mixture into the pre-calibrated bottle.
8. Rinse the mortar and pestle with 5 mL of suspension vehicle and transfer into the bottle.
Note: Repeat this step once.
9. Add a sufficient quantity of the suspension vehicle directly into the bottle to the pre-calibrated mark.
10. Cap the bottle and shake thoroughly to disperse the suspension.
11. Store the suspension at room temperature or under refrigeration for up to 2 months. Shake well before using.
TABLE 1. SOURCE INFORMATION OF SUSPENSION VEHICLES.
VEHICLES VENDOR
CATALOG
NUMBER
NDC
NUMBER
LOT NUMBER AND
EXPIRATION DATE
Ora-Sweet Perrigo - 0574-0304-16 7260310, 6/30/2020
Ora-Sweet SF Perrigo - 0574-0302-16 5211709, 5/2019
Ora-Plus Perrigo
::..v 0574-0303-16 7219887, 5/31/2019
Oral Mix Medisca - 38779-2512-8 137502/A, 10/2019
Oral Mix SF Medisca - 38779-2600-8 137485/A, 08/2018
SyrSpend SF Fagron 805359 51552-1123-5 16A05-U06-028553,1/5/2019
UniSpend anhydrous,
; sweetened
Fagron 906909 51552-1544-05 17K01-U05-040766 11/01/2019
UniSpend anhydrous,
unsweetened
Fagron 806910 51552-1545-05 17K01-U08-04074111/01/2019
formulations (SB and SF) which are easy 
to prepare by pharmacists, easy to dose, 
palatable, and exhibit satisfactory physical 
properties.
For nonsterile dosage forms prepared 
by extemporaneous compounding, the 
storage conditions and beyond-use dates 
(BUD) are specified in the United States 
Pharmacopeia? Without any stability data, 
compounded suspensions in aqueous vehi­
cles have to be stored under refrigeration 
with a BUD of only 14 days. The ESL mole­
cule has an ester functional group which is 
prone to hydrolysis catalyzed by extreme 
pH and heat. However, given the low-water 
solubility of this drug,’^ the rate of hydroly­
sis is expected to be slow for a suspension 
formulation, especially when buffered pro­
perly by the vehicle. The second objective of 
this study was to conduct a stability evalua­
tion on the selected oral suspensions with a 
goal to extend the BUD for up two months at 
both room temperature (RT) and under re­
frigeration. This will provide flexibility for 
the pharmacies to plan the compounding 
activities and manage the inventory.
METHODS
MATERIALS
The pure active pharmaceutical ingre­
dient (API) powder of ESL (Lot 1040155) 
and 600-mg Aptiom tablets (Lot PNKN; 
EXP June 2018) were provided by Sunovion 
Pharmaceuticals Inc. (Marlborough, 
Massachusetts). The suspension vehicles 
were purchased from multiple 
vendors as listed in Table 1.
NDC = National Drug Code: SF = sugar free
INITIAL SCREENING
Prototype suspension for­
mulations of 40-mg/mL ESL 
were prepared at a 30-mL batch 
size for initial screening. The 
following procedures were used 
to prepare each formulation. A 
2-oz glass bottle was pre-cali­
brated with 30 mL of purified 
water. Two 600-mg Aptiom tab­
lets were crushed and thorou­
ghly triturated in a 4-oz glass 
mortar. About 10 mL of vehicle
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was added to the mortar in -1-mL increments with trituration until 
a smooth suspension was obtained. The suspension was carefully 
poured into the pre-calibrated bottle, followed by two mortar rinses 
of 5 mL of vehicle each. Finally, a sufficient amount of vehicle was 
added directly into the bottle to the pre-calibrated mark. Each bottle 
was shaken thoroughly to disperse the suspension. The ease of pre­
TIBLE 2. PALATABILITY EVALUATION RUBRIC.
TASTE SCALE OF 1 TO 5
(LEAST TO MOST INTENSE; 5 = MOST)
Bitter 1 2 3 4 5
Sweet 1 2 3 4 5
Sour 1 2 3 4 5
Salty !■ 2 3 4 5
Oily 1 2 3 4 5
Metallic 1 2 3 4 5
ODOR
SCALE OF 1 TO 5
(LEAST TO MOST INTENSE BAD 
ODOR; 5 = MOST)
1 2 3 4 5
TEXTURE
SCALE OF 1 TO 5 (LEAST TO MOST 
GRITTY; 5 = MOST)
12 3 4 5
IRRITATION
SCALE OF 1 TO 5 
(LEAST TO MOST IRRITATING/ 
AVERSIVE; 5 = MOST)
1 2 3 4 5
AFTERTASTE
(up to 10 minutes
SCALE OF 1 TO 5 (LEAST TO MOST 
AVERSIVE AFTERTASTE; 5 = MOST)
after rinse) 1 2 3 4 5
TABU 3. PROTOTYPE ORAL SUSPENSIONS OF 40 MG/ML 
ESLICARBAZEPINE ACETATE.
FORMULATION SUGAR-BASED
NUMBER VEHICLE OR SUGAR-FREE
118-1 Ora-Sweet Sugar-based
118-2 Ora-Sweet SF Sugar-free
118-3 50:50 v/v Ora-Sweet:
Ora-Plus
Sugar-based
118-4 50:50 v/v Ora-Sweet SF:
Ora-Plus
Sugar-free
118-5 Oral Mix Sugar-based
118-6 Oral Mix SF Sugar-free
.118-7 SyrSpend SF Sugar-free
118-8 UniSpend anhydrous
sweetened
Sugar-based
118-9 UniSpend anhydrous
unsweetened
Sugar-free
paration and initial observations were recorded immediately. The 
suspensions were then evaluated for ease of dosing, palatability, and 
physical properties.
The ease of dosing was first evaluated using the graduated oral 
syringes (Catalog 2111; Total Pharmacy Supply, Inc., Arlington, 
Texas). It was observed that some suspensions were difficult to 
expel from the syringes. Therefore, the oral dosing spoons (Catalog 
2102; Total Pharmacy Supply, Inc.) were added to the evaluation. 
Palatability of the suspensions was evaluated by the two study 
investigators using the rubric listed in Table 2. A teaspoonful dose 
(5 mL) of each suspension was swished around in the mouth for 
10 seconds and spat out. The mouth was rinsed with a sufficient 
amount of warm water, and the palatability results were recorded 
immediately. A minimum of a 2-hour-wait period was maintained 
before the next sample. Evaluation of the physical properties of 
the suspensions included particle settling, re-suspendability, and 
foaming. One set of the suspensions were inspected and re-sus­
pended daily for 4 days. A second set of the suspensions were left 
undisturbed on a laboratory bench for 8 weeks, and camera images 
were taken daily during the first week and weekly afterwards. 
Re-suspendability of these suspensions was evaluated at the end of 
the 8-week period.
TWO-MONTH STABILITY STUDY
Two lead formulations of 40-mg/mL ESL in 50:50 v/v Ora- 
Sweet:Ora-Plus or Ora-Sweet SF:Ora-Plus, were selected for the 
two-month stability study. Batches of 120-mL suspensions were 
prepared using the following method:
Method of Preparation of 120-mL Suspension Batches
1. Calculated the required quantity of each ingredient for the total 
amount to be prepared.
2. Pre-calibrated a 4-oz amber prescription bottle with 120 mL of 
purified water.
3. Crushed and thoroughly triturated eight 600-mg Aptiom tablets 
in an 8-oz glass mortar.
4. Added about 40 mL of the vehicle to the mortar in -lO-mL incre­
ments with trituration until a smooth suspension was obtained.
5. Poured the suspension carefully into the pre-calibrated bottle 
followed by three mortar rinses of 20 mL of the vehicle each.
6. Added a sufficient amount of vehicle directly into the bottle, to 
the pre-calibrated mark.
7. Shook the bottle thoroughly to disperse the suspension.
8. Transferred and packaged aliquots of the suspensions, 30 mL 
each, in 2-oz amber prescription bottles for the stability study.
9. Stored the bottles at RT or under refrigeration (2°C to 8°C).
Three replicates were included for each formulation. At 0,1-week, 
2-week, 4-week, 6-week, and 9-week time points, the bottles were 
shaken for re-suspension, and samples were withdrawn for visual
www.IJPC.com International Journal of Pharmaceutical Compounding
Vol. 22 No. 5 I September October | 2018 ^35
TABLE 4. PROTOTYPE SUSPENSION FORMULATIONS AND INITIAL SCREENING RESULTS.
FORMULATION EASE OF EASE OF ACCEPTABLE PARTICLE SETTLING RE-
NUMBER PREPARATION DOSING PALATABILITY (AFTER 4 DAYS) SUSPENDABILITY
118-1 il* Yes Yes Yes No
118-2 Yes Yes Yes Yes Yes
118-3 Yes Yes Yes NO Yes
118-4 Yes Yes Yes No Yes
118-5 Yes Yes Yes No Yes
118-6 Yes Yes Yes No Yes
118-7 No Yes Yes -/ No Yes
118-8 Yes No“ Yes Yes Yes
118-9 Yes No" No Yes Yes
“It was easy to withdraw the suspension into the syringe, but it was very difficult to expel the suspension for dosing. There were no issues with dosing spoons.
TABLE 5. THE pH RESULTS OF THE TWO-MONTH STABILITY STUDY (/l=3).
SAMPLE STORAGE
2°C to 8°C
RT
pH
TIME 0
4.45 ± 0.01
4.46 ± 0.01
1 WEEK
4.46 ± 0.01
4.46 ± 0.01
2 WEEKS
4.48 ± 0.02
4.48 ± 0.03
4 WEEKS
4.46 ± 0.02
4.45 ± 0.01
6 WEEKS
4.51 ± 0.02
4.51 ± 0.01
9 WEEKS
4.49 + 0.02
4.48 ± 0.01
40-mg/mL ESL suspension 
in 50:50 v/v
Ora-Sweet:Ora-Pius
40-mg/mL ESL suspension 
in 50:50 v/v
Ora-Sweet SF:Ora-Pius
2°C to S-C
RT
4.39 + 0.01
4.40 ± 0.01
4.42 ± 0.01
4.44 ± 0.02
4.43 ± 0.01
4.42 ± 0.01
4.42 ± 0.01
4.43 ± 0.01
4.44 ± 0.01
4.43 ± 0.01
4.42 + 0.01
4.42 ± 0.02
ESL = esiicarbazepine acetate; RT = room temperature
TABLE 6. HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC RESULTS OF THE TWO-MONTH STABILITY STUDY (/l = 3).
SAMPLE STORAGE
2°C to 8”C
RT
% LABEL CLAIM
TIME 0
101.8 ± 1.4
102.2 +1.4
1 WEEK
102.1 ± 0.4
101.2 ± 0.3
2 WEEKS
100.9 ± 0.1
102.5 ± 1.5
4 WEEKS
102.7 ± 0.2
103.3 ± 1.1
6 WEEKS
101.5 ± 0.4
102.4 ± 0.8
9 WEEKS
102.3 ± 0.2
103.4 ± 0.6
40-mg/mL ESL suspension 
in 50:50 v/v
Ora-Sweet:Ora-Pius
40-mg/mL ESL suspension 
in 50:50 v/v
Ora-Sweet SF:Ora-Plus
2“C to 8”C
RT
100.4 ± 0.3
101.9 ± 3.4
100.8 ± 1.3
99.6 ± 0.3
101.5 ± 2.1
101.3 ± 0.5
101.3 ± 0.6
102.1 ± 0.7
100.9 ± 0.9
102.0 ± 0.9
101.0 ± 0.3
101.8 ±0.5
ESL = esiicarbazepine acetate: RT = room temperature
inspection, pH measurement, and 
high-performance liquid chroma­
tographic (HPLC) analysis.
For the HPLC analysis, a 
1.25-mL aliquot from each sta­
bility sample was transferred 
into a 50-mL volumetric flask 
and diluted to the line with 
50:50 v/v methanohwater. The 
expected drug concentration 
was 1 mg/mL. The flasks were 
sonicated for 10 minutes and
allowed to cool to RT. About 1 mL of sample from each 
flask was filtered through a 0.45-|im polytetrafluoro- 
ethylene membrane into an autosampler vial for the 
HPLC analysis (see below for details). Please note that 
it was not possible to transfer the desired 1.25-mL 
volume accurately by the routine pipetting technique 
for viscous suspensions. Instead, the samples were 
transferred with weight monitoring. To be more specif­
ic, each volumetric flask was tared on a balance, and 
the sample was added slowly to the flask using a pipet 
until the target weight was reached. The target weight 
values were 1.44 g and 1.28 g for the Ora- Sweet/Ora-
Plus and Ora-Sweet SF/Ora-Plus samples, 
based on the measured density values of 
1.155 g/mL and 1.023 g/mL, respectively.
HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHIC ANALYSIS
A stability-indicating HPLC method was 
previously developed and implemented in 
the investigators’ laboratory for ESL sus­
pensions intended for enteral feeding tubes. 
The method was verified to be suitable for
8
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FIGURE IR. PHYSICAL APPEARANCE OF ESLICARBAZEPINE ACETATE SUSPENSION FORMULATIONS AFTER 0 
TO 5 DAYS.
DAY 118-1 118-2 118-3 118-4 118-5 118-6 118-7 118-8 118-9
the analysis of the current 
oral suspension formula­
tions. Briefly, the analysis 
was performed using a 
Shimadzu HPLC system 
(Model LC-2010AHT) e- 
quipped with a Phenomenex 
CIS column (Luna, 150 x 
4.6 mm, 311, and 100 A). The 
mobile phase consisted of 
a methanol and water mix­
ture (50:50 v/v) with 0.1% 
trifluoroacetic acid. The 
mobile phase flow rate was 
set at 0.8 mL/minute, and 
the column oven was set at 
40°C. The sample injection 
volume was 3 nL, and the 
detection wavelength was 
set at 230 nm. Under these 
conditions, the retention 
time of ESL was observed to 
be about 8.9 minutes.
For calibration purposes, 
standard solutions of 
0.8 mg/mL, 0.9 mg/mL,
1.0 mg/mL, 1.1 mg/mL, and 
1.2 mg/mL ESL were pre­
pared from pure drug powder 
in 50:50 v/v methanohwa- 
ter. This range encom­
passes 80% to 120% of the 
expected drug concentra­
tion in the diluted stability 
samples for HPLC analysis. 
A calibration curve was 
constructed on each day of 
the analysis by plotting the 
peak area of ESL against 
concentration. The curves 
were found to be linear 
over the concentration 
range of the standards with 
= 0.994 or better. The 
middle standard was also 
injected three times through­
out the analysis on each 
day to assess the method 
precision. The intra-day 
and inter-day coefficients 
of variation were 
within 0.6%.
www.IJPC.com International Journal of Pharmaceutical Compounding
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RESULTS AND 
DISCUSSION 
INITIAL SCREENING
Nine prototype suspension 
formulations (118-1 to 118-9) 
were prepared in commercially 
available liquid vehicles as listed 
in Table 3. Both sugar-based 
(SB) and sugar-free (SF) systems 
were included. The first seven 
vehicle systems are commonly 
used by pharmacists. The last 
two are relatively new anhydrous 
(lipid-based) vehicles, which 
can potentially minimize the 
hydrolytic degradation of drug 
molecules, such as ESL. The 
40-mg/mL drug concentration 
was chosen so as to provide a 
dose of200-mg ESL in a conven­
ient 5-mL volume (equivalent to 
a l-teaspoonful measurement in 
the U.S.).
The initial screening data are 
summarized in Table 4. All nine 
formulations except 118-7 were 
relatively easy to prepare from 
the 600-mg strength Aptiom 
tablets. The vehicle used in for­
mulation 118-7, SyrSpend SF, 
has a high intrinsic viscosity, 
which led to a very thick drug 
suspension and significant 
drug loss during transfer steps. 
The anhydrous (lipid-based) 
formulations, 118-8 and 118-9, 
exhibited a lower viscosity than 
all other formulations (aque­
ous based) and were easier 
to transfer from mortar to 
prescription bottles. In terms of 
ease of dosing, aU suspensions, 
except formulations 118-8 and 
118-9, were compatible with oral 
syringes and dosing spoons. The 
palatabUity was also found to 
be acceptable for most formu­
lations whth an average score 
of <3 (out a scale of 5) for each 
evaluation category. Formulation 
118-9 was scored 3.5 for its oily
taste and thus considered unacceptable. After 4 days 
of storage at RT, some particle settling was observed in 
formulations 118-2,118-8, and 118-9. The settling was 
not unexpected, since the 118-2 contains no suspend­
ing agents, and the two anhydrous vehicles have a low 
intrinsic viscosity. Nevertheless, all formulations ex­
hibited satisfactory re-suspendabUity upon shaking, 
with no foaming issues.
A second set of the suspension formulations were 
used to monitor the particle settling behavior over an 
extended period of 8 weeks at RT without any phys­
ical disturbances. The camera images from day 0 to 
5 days eu'e shown in Figure lA, and the ones from 1 
week to 8 weeks are shown in Figure IB. All suspen­
sions retained their structure on days 0,1, and 2. On 
Day-3, suspensions 118-8 and 118-9 exhibited signs 
of particle settling along with the formation of a layer 
of clear vehicle at the top surface. Suspensions 118-1 
and 118-2 also showed initial signs of settling behavior.
although a clear separation of vehicle and 
the particles was not observed. The settling 
behavior of these four suspensions pro­
gressed over the following days and weeks. 
Suspensions 118-5 and 118-6 started to 
settle at the end of Week-1 and progressed 
over the following weeks. Suspension 118-5 
appeared to settle at a faster rate compared 
to 118-6. Suspensions 118-3 and 118-4 began 
settling during Week-2 and progressed over 
the following weeks. Similar to the obser­
vations above, suspension 118-3 appeared 
to settle at a greater rate compared to 118-4. 
Suspension 118-7 appeared to be most stable 
against settling among all of the formula­
tions evaluated. This formulation retained 
its structure throughout the testing period. 
The settling behavior of prepared suspen­
sion formulations appeared to be a function
International Journal of Pharmaceutical Compounding
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of the intrinsic viscosity of the vehicles. Similar to previous obser- were selected from the initial screening work based on ease of pre-
vations, all formulations were re-suspended satisfactorily upon paration, ease of dosing, palatability, and physical properties. The
shaking after 8 weeks of storage at RT. formulations consisted of 40 mg/mL of eslicarbazepine acetate in
Based on the initial screening data, formulations 118-3 and 118-4 50:50 v/v Ora-Sweet:Ora-Plus (sugar-based) or Ora-Sweet SF:Ora-
were selected as the leads for additional evaluation. Formulation Plus (sugar-free). Both formulations exhibited satisfactory physical
118-3 contained 50:50 v/v Ora-Sweet:Ora-Plus (sugar based), and and chemical stability over the two months of storage period at RT
formulation 118-4 contained 50:50 v/v Ora-Sweet SF:Ora-Plus or under refrigeration (2°C to 8°C). The vehicles also contained pre-
(sugar free). They provided the optimal balance of all the desired servatives to prevent potential microbial growth. The recommended
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CONCLUSION
This study investigated oral suspension formulations of ESL
prepared by extemporaneous compounding. Two formulations
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